Mediso introduces true theranostic TheraMAX SPECT/CT

HAMBURG, Germany, Oct. 21, 2024 /PRNewswire/ -- Mediso is unveiling its new AnyScan® TRIO SPECT/CT, TheraMAX* scanner at the annual meeting of European Association of Nuclear Medicine (EANM).

The new TheraMAX is specifically designed for serving the clinical needs of theranostic imaging. It features detectors and collimators developed for Targeted Radionuclide Therapies carried out with radioisotopes emitting not only alpha and beta particles, but high and ultra-high energy gamma photons like ¹⁷⁷Lu, ²¹²Pb, ¹³¹I, ²²⁵Ac and beyond.

The TheraMAX is equipped with three, large surface detectors (up to 5x larger than 12-detector CZT systems) surrounding the patients completely (360°). The 15.9mm thick NaI crystals ensure improved sensitivity for high energy photons, while the high-density sensor arrangement (123 PMT per detector head) allows high spatial resolution leading to PET-like image quality in all NM applications.

The 300% sensitivity gain compared to conventional dual-detector systems enables whole body ²²⁵Ac SPECT/CT in theranostic imaging, while this extreme total system response also allowing ultra-fast quantitative total-body SPECT/CT scans with ^99mTc and LEHR-HS collimator. Moreover, novel multi-pinhole technology combined with Triple-NaI-Detectors provide outstanding performance for cardiology and neurology.

The integrated CT offers three performance levels: low-dose diagnostic scans, ultra-low dose protocol for attenuation and scatter correction and even "Zero-Dose" imaging with AI-powered SyCT** (Synthetic CT).

The first global site for the TheraMAX is the University Hospital Regensburg, Germany. Following a recent installation, Professor Dr. Dirk Hellwig, the head of the Department of Nuclear Medicine said "the new scanner will boost our diagnostic and theranostic workflow, leading to better patient care and it also opens new possibilities in clinical research".

"With the development of the new TheraMAX, we extended the imaging capabilities of nuclear medicine departments by improving the diagnostic confidence of SPECT/CT examinations close to PET/CT" said Istvan Bagaméry, Managing Director of Mediso Ltd. "The TheraMAX transforms the clinical routine also with ultra-fast quantitative total-body scans."

About Mediso

Mediso is a leading manufacturer of molecular imaging techniques to the health care and medical research institutions of the world.

Mediso has a complete profile of imaging research, system development, manufacturing, selling and servicing of multi-modality imaging devices. With over 35-years of expertise, 1400 clinical and 350 preclinical systems installed in over 100 countries, Mediso offers complete solutions from imaging devices to evaluation and quantification software.

*TheraMAX is the configuration name of AnyScan TRIO SPECT/CT with MAX/123-15.9 detector

**Regulatory approval pending

Contact:

info@mediso.com
https://mediso.com/

Photo - https://mma.prnewswire.com/media/2526761/Mediso.jpg
Logo - https://mma.prnewswire.com/media/2526762/Mediso_Logo.jpg